Abstract #S230.) Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with Chronic Graft-Versus-Host Disease After ≥2 Prior Lines of ...

Investing.com -- Shares of Incyte (NASDAQ: INCY) climbed 7% today after the biopharmaceutical company announced that multiple ...

Poster presentations will cover a range of topics, such as the Phase 3 study of Axatilimab for chronic graft-versus-host disease and the efficacy of the BET protein inhibitor INCB057643 in myeloid ...

Incyte's stock valuation is on the higher side given looming patent expiries for Jakafi and Opzelura, and uncertain pipeline ...

Incyte Corporation (NASDAQ:INCY) saw its stock surge 7% after the company announced that multiple research presentations, ...

Video content above is prompted by the following: Treatment of patients with chronic graft-vs-host disease (cGVHD) on axatilimab often involves collaboration between transplant centers and community ...

Revuforj is Syndax's second first-in-class approval for 2024, coming after the company and partner Incyte got a green light from the FDA for anti-CSF-1R antibody Niktimvo (axatilimab) as a third ...

Incyte trades -8.61% away from its average analyst target price of $73.88 per share. The 23 analysts following the stock have set target prices ranging from $52.0 to $96.0, and on average have given ...

June 14, 11:00 – 11:15 a.m. EDT [5:00 – 5:15 p.m. CEST]. Abstract #S230.) Trial in Progress: A Randomized, Open-Label, Phase 3 Study of Axatilimab Versus Best Available Therapy in Patients with ...

Video content above is prompted by the following: Significant advances in chronic graft-vs-host disease (cGVHD) prophylaxis include 2 groundbreaking clinical trials. The BMT CTN 1703 study compared ...